12.07.2018 BB BIOTECH AG  CH0038389992

DGAP-Adhoc: BB Biotech AG reports preliminary results for 1H 2018


 
DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning/Half Year Results BB Biotech AG reports preliminary results for 1H 2018 12-Jul-2018 / 18:05 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Media Release, July 12, 2018 BB Biotech AG reports preliminary results for 1H 2018 In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the first half year of 2018. Based on preliminary unaudited consolidated results, BB Biotech closed the first half year of 2018 with a loss of around CHF 70 mn (CHF 478.4 mn profit in the corresponding period of the previous year). As an investment company, the result reflects the performance of the stocks it holds in its investment portfolio. BB Biotech's share price increased 8.4% in CHF and 8.2% in EUR during the corresponding period. The interim report as of June 30, 2018 will be published on July 20, 2018. For further information: Investor Relations Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 00 Dr. Silvia Schanz, ssc@bellevue.ch Maria-Grazia Iten-Alderuccio, mga@bellevue.ch Claude Mikkelsen, cmi@bellevue.ch Media Relations Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland, tel. +41 44 267 67 07 Tanja Chicherio, tch@bellevue.ch www.bbbiotech.com Company profile BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science. --------------------------------------------------------------------------- 12-Jul-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: BB BIOTECH AG Schwertstrasse 6 8200 Schaffhausen Switzerland Phone: +41 52 624 08 45 E-mail: info@bbbiotech.com Internet: www.bbbiotech.ch ISIN: CH0038389992 WKN: A0NFN3 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX End of Announcement DGAP News Service --------------------------------------------------------------------------- 703867 12-Jul-2018 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 324,56 775,68 1.392,56 616,82 8,84 624,17 5,13 0,00
EBITDA1,2 304,81 760,23 1.365,47 602,92 -746,78 588,33 -418,21 0,00
EBITDA-Marge3 93,91 98,01 98,05 97,75 -8.447,74 94,26 -8.152,24 0,00
EBIT1,4 304,81 760,23 1.365,47 602,92 -746,78 588,33 -418,21 0,00
EBIT-Marge5 93,91 98,01 98,05 97,75 -8.447,74 94,26 -8.152,24 0,00
Jahresüberschuss1 304,56 760,12 1.365,40 602,85 -747,71 587,80 -418,27 0,00
Netto-Marge6 93,84 97,99 98,05 97,74 -8.458,26 94,17 -8.153,41 0,00
Cashflow1,7 111,50 95,50 112,98 48,36 107,46 225,26 95,66 0,00
Ergebnis je Aktie8 5,10 13,34 24,11 10.79 -13,51 10,62 -7,55 4,70
Dividende8 0,73 1,15 2,36 2,63 2,58 2,85 2,68 2,50
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
BB Biotech
WKN Kurs in € Einschätzung Börsenwert in Mio. €
A0NFN3 60,550 Kaufen 3.587,59
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
14,42 4,87 2,916 13,42
KBV KCV KUV EV/EBITDA
1,45 37,50 699,33 -8,924
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
Hauptversammlung
2,68 2,50 4,43 19.03.2020
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
24.04.2020 24.07.2020 18.10.2019 21.02.2020
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
5,86% 1,88% 16,67% 10,80%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu BB BIOTECH AG  ISIN: CH0038389992 können Sie bei DGAP abrufen

Biotechnologie , A0NFN3 , BBZA , XETR:BBZA